Thank you for your download request
https://www.certara.com/thank-you-content-download-services/
1493 results
What’s New in the Simcyp™ Simulator – from Regulatory Advances to New Modalities
Already the most sophisticated technology for physiologically based pharmacokinetic modeling (PBPK), the Simcyp Simulator has added a range of new advances in its recently release (version 23). This webinar, hosted by the subject matter expert scientists at Simcyp, will share these new capabilities and review the features that have enabled the Simulator to be leveraged … Continued
https://www.certara.com/on-demand-webinar/whats-new-in-the-simcyp-simulator-from-regulatory-advances-to-new-modalities/Waiving clinical studies & accelerating drug development for kinase inhibitor drugs eBook
Speed up Drug Development for Kinase Inhibitors: Free eBook Unlock the key to faster drug development with our eBook, “Waiving Clinical Studies & Accelerating Drug Development for Kinase Inhibitor (KI) Drugs.” Whether you’re in pre, early, or late clinical stages to post-marketing, this essential resource offers real-world case studies and insights into the power of … Continued
https://www.certara.com/waiving-clinical-studies-accelerating-drug-development-for-kinase-inhibitor-drugs-ebook/Thank You – Content Download – Simcyp
How about a free demo of the Simcyp™ PBPK Simulator? Complete the form to book your no-obligation demo of the standard software for Population-based Physiologically Based Modeling and Simulation… and see how better off you could be with Simcyp!
https://www.certara.com/thank-you-content-download-simcyp/CERTAINTY by Certara 2024
Transcript: The Certara community and interdisciplinary industry experts and scientists from model and form drug development bio simulation, clinical pharmacology, regulatory science, and software development come together for Certainty. Certara’s first annual client summit. This coming May fourteenth through sixteenth in Philadelphia at Convene. We will unite to share future visions, strategies, industry trends, and … Continued
https://www.certara.com/video/certainty-by-certara-2024/Certara Reports Fourth Quarter 2023 Financial Results
Provides Full Year 2024 Financial Guidance PRINCETON, N.J.— February 29, 2024– Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today reported its financial results for the fourth quarter of fiscal year 2023. Fourth Quarter Highlights: “We are encouraged by our strong fourth quarter results, driven by improved execution across both software and services,” said William … Continued
https://www.certara.com/pressrelease/certara-reports-fourth-quarter-2023-financial-results/Planning for a Successful EMA Policy 0070 Submission
https://www.certara.com/article/planning-for-a-successful-ema-policy-0070-submission/
P21 Live 2024
The 2024 Pinnacle 21 User Group Meeting is your chance to explore, with its architects and your peers, our newly expanded suite of capabilities, from metadata management to accelerated SDTM generation. Learn best practices from case studies, ask questions about our roadmap, and gather with your fellow data leaders. Location Convene CityView, 30 S 17th St, … Continued
https://www.certara.com/live-events/p21-live-2024/How to Navigate the FDA Landscape for an Orphan Drug
Rare diseases are a public health priority. FDA has launched several programs and a final guidance to address the unmet need for orphan drugs.
https://www.certara.com/blog/how-to-navigate-the-fda-landscape-for-an-orphan-drug/Dose Optimization Considerations for Targeted Radiation Therapies
The acquisitions of targeted radiation therapy companies (TRT) Point Biopharma by Eli Lilly and RayzeBio by Bristol Meyer Squibb have sparked investors’ interest in this therapeutic class. A growing number of companies are now developing TRTs, and GlobalData reports that venture capital deals in the field have grown 550% to $408 million in 2023.1 The … Continued
https://www.certara.com/blog/dose-optimization-considerations-for-targeted-radiation-therapies/